Rebiotix Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Rebiotix Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013521
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that offers treatment solutions for debilitating diseases by harnessing the power of the human microbiome. The company harnesses microbiota restoration therapy, a drug delivery platform that releases healthy, live and human-derived microbes into the intestinal tract of a patient to treat diseases. The company’s lead product, RBX2660 is a non-antibiotic therapy that is used to treat clostridium difficile infection. It also develops therapies for ulcerative colitis, hepatic encephalopathy and multi-drug resistant organisms. Rebiotix is headquartered in Roseville, Minnesota, the US.

Rebiotix Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rebiotix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Rebiotix Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Rebiotix Raises 8.5 Million in Venture Financing 10
Rebiotix Raises USD25 Million in Series B Financing 11
MikrobEX Secures US$2.8 Million In Venture Financing 12
Rebiotix Inc – Key Competitors 13
Rebiotix Inc – Key Employees 14
Rebiotix Inc – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Corporate Communications 16
Jun 20, 2017: Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Rebiotix Inc, Pharmaceuticals & Healthcare, Key Facts 2
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rebiotix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rebiotix Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Rebiotix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Rebiotix Raises 8.5 Million in Venture Financing 10
Rebiotix Raises USD25 Million in Series B Financing 11
MikrobEX Secures US$2.8 Million In Venture Financing 12
Rebiotix Inc, Key Competitors 13
Rebiotix Inc, Key Employees 14

★海外企業調査レポート[Rebiotix Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Engie SA:企業の戦略・SWOT・財務情報
    Engie SA - Strategy, SWOT and Corporate Finance Report Summary Engie SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Universal Music Group Inc:企業の戦略的SWOT分析
    Universal Music Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Alphatec Holdings Inc (ATEC):医療機器:M&Aディール及び事業提携情報
    Summary Alphatec Holdings Inc (Alphatec) is a medical technology company that focuses on the design, development and marketing of spinal fusion technology products and solutions for the treatment of spine disorders. The company’s major products include anterior cervical plate system, posterior cervi …
  • Thomson Reuters Corporation:企業の戦略・SWOT・財務情報
    Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report Summary Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • IncellDx Inc:医療機器:M&Aディール及び事業提携情報
    Summary IncellDx Inc (IncellDx) is a single cell diagnostic company that develops transformative diagnostic and prognostic clinical patient information technologies. The company detects and monitors life threatening viral diseases in the areas of cervical cancer, HIV and AIDS, hepatitis, and organ t …
  • Daisy IT Group Ltd:企業の戦略的SWOT分析
    Daisy IT Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Livzon Pharmaceutical Group Co Ltd (000513):企業の財務・戦略的SWOT分析
    Summary Livzon Pharmaceutical Group Co Ltd (Livzon) a subsidiary of Joincare Pharmaceutical Group Industry Co Ltd, is a pharmaceutical company which is engaged in developing, manufacturing and distributing pharmaceutical products. The company provides preparation drug products, bulk medicines and in …
  • Nexstim Plc (NXTMH)-医療機器分野:企業M&A・提携分析
    Summary Nexstim Plc (Nexstim) is a medical technology company, which focuses on navigated brain stimulation (NBS) to improve rehabilitation in stroke patients non-invasively . Its NBS system, which is FDA cleared and CE-marked, applies navigated transcranial magnetic stimulation (nTMS) device for pr …
  • Navidea Biopharmaceuticals Inc (NAVB)-医療機器分野:企業M&A・提携分析
    Summary Navidea Biopharmaceuticals Inc (Navidea) is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. Its key product, Lymphoseek (technetium Tc 99m tilmanocept) injection, is a radiopharmaceutical agent used i …
  • Enterprise Diversified Inc (SYTE):企業の財務・戦略的SWOT分析
    Summary Enterprise Diversified Inc (Enterprise Diversified), formerly Sitestar Corp, is a technology company that offers asset management, home services, internet, and real estate programs. The company offers consumer and business-grade internet access, wholesale managed modem services for downstrea …
  • Lexicon Pharmaceuticals Inc (LXRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program …
  • Sparton Resources Inc (SRI):企業の財務・戦略的SWOT分析
    Summary Sparton Resources Inc (Sparton Resources) is a diversified company that acquires and develops oil and gas properties in North America and China. The company’s products include vanadium, natural gas, crude oil, gold, and vanadium flow batteries, among others. Its energy projects comprise Sier …
  • Fiskars Corporation:企業の戦略・SWOT・財務情報
    Fiskars Corporation - Strategy, SWOT and Corporate Finance Report Summary Fiskars Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease me …
  • Warp Drive Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary Warp Drive Bio Inc (Warp Drive) is a natural products provider. The company utilizes the proprietary genomic mining and small molecule assisted receptor targeting platform to develop novel medicines. Its SMART platform offers solutions to the pharmaceutical opportunities. Warp Drive's integr …
  • Lay Hong Berhad (Lay Hong):企業の財務・戦略的SWOT分析
    Lay Hong Berhad (Lay Hong) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Taiga Biotechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiga Biotechnologies Inc (Taiga Biotech) is a biopharmaceutical company that develops protein and cellular therapies. The company develops therapies for diseases including cancers and infectious diseases. It provides pipeline products such as programs such as stem cell therapy and target sp …
  • Hillenbrand Inc (HI):企業の財務・戦略的SWOT分析
    Hillenbrand Inc (HI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SMART Global Holdings, Inc. (SGH):企業の財務・戦略的SWOT分析
    SMART Global Holdings, Inc. (SGH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Banco Popular Dominicano S.A.:企業の戦略・SWOT・財務情報
    Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆